Micron Biomedical https://validator.w3.org/feed/docs/rss2.html Impact and Cost-Effectiveness of Microarray Technology Featured in BMJ Journal Micron Biomedical Micron Biomedical Showcases Vaccine Tech at SXSW Company Micron Biomedical Speaks at World Vaccine Congress Micron Speaks at Bio 2025 on Overcoming Challenges to Disrupt the Industry with Dissolvable Microarray Technology Micron Biomedical Names Health Education and Empowerment Advocate, Dr. Jayne Morgan, to Board of Advisors “a groundbreaking advancement for public health” Science Magazine “significant promise for the future of vaccine development and global health” says Clinical Trial Vanguard of the Micron, Emory and CDC collaboration on next-generation rotavirus vaccines Micron Biomedical Wins the “Biotech Medical Innovation” Award at Boston Biotech Week Micron Biomedical Raises $16M+ to Expand Manufacturing Micron Biomedical Joins J2 Ventures Annual Meeting Micron Biomedical’s Measles Patch Tops Gavi’s Priority List Micron Biomedical Presents Breakthrough Tech at MVADS25 Micron Recognized at ViE & WVCDC Awards Micron Biomedical Announces The Lancet Publication of Positive Phase 1/2 Data From First Clinical Trial of Needle-Free Vaccines in Children Contact Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles World Economic Forum Spotlights Micron’s Dissolvable Microneedles and the Opportunity to Increase Vaccine Uptake Dr. Jayne Morgan Labiotech Spotlights Micron Biomedical as a Leader in Needle-Free Vaccines Endpoints News: “Micron Biomedical has started 2025 on a positive note” Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World’s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in Infants FiercePharma Spotlights Micron Biomedical’s Progress to Commercializing a Life-Saving “Button” Reuters Spotlights Micron’s Progress Toward Mass Production of Its Proprietary Microarray Technology Brian Bernick, MD Dr. Sandeep Patel Micron Biomedical Recognized as a Breakthrough Scientific Innovation in the Prix Galien Start-Up Category Newsweek Spotlights Micron Technology as Part of Bill Gates’Plan to Change Vaccines Mathew Goldman BBC Spotlights “Extremely Promising” Micron Biomedical Data Publication in The Lancet The Telegraph Spotlights Micron Biomedical Data Publication in The Lancent Virtually Ouch-Free? Promising Early Data On A Measles Vaccine Delivered Via Stick-On Patch Micron Biomedical Presents at the White House Summit on the Future of COVID-19 Vaccines Startups’ Patch Technologies Could Extend Reach of Vaccines Atlanta News First Spotlights Micron Biomedical’s “Game Changing Technology” Micron Biomedical CEO to Speak at Reuters Signature Event in a Health Equity Fireside Chat Micron Biomedical Spotlighted by GAVI, the Vaccine Alliance Micron Joins Global Life Science Industry Leaders at BioEurope Micron Recognized as Innovation Shaping the Future of Infectious Disease at BioFuture 2023 Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles Technology CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant to Advance Learnings from COVID-19  Protected: Test – Micron Biomedical Protected: Applications Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines Dr. Seth Berkley Dr. Gregory Poland Micron Biomedical Expands World-Renowned Advisory Team with Appointment of Medtech Innovation Leader, Sandeep Patel, PhD Ahead of Commercial Manufacturing of Its Needle-Free Technology